Copy

NeoStem Registered Trials

NeoStem Registered Trials
Phase I Through Phase III Development
February 13, 2015

 
Stem Cell Therapeutics Markets Report
by Kahoma Information
 
There are more than 4,000 research projects underway for stem cell therapies throughout the world. Only about a dozen companies worldwide are currently evaluating stem cell therapies in late stage clinical trials. NeoStem is one of the companies in this advanced stage of development. Other companies discussed in this report include those which have also registered trials in Phase I through Phase III development. 

Kalorama Information’s Stem Cell Therapeutics Markets conducts in-depth research into the stem cell market opportunity by assessing current technology performance, new developments, pricing trends and government positions on the topic. A combination approach – using both a bottom-up model and comparing data with a top-down analysis – was used to determine market size and market forecasts. Over the next several years, as researchers introduce a growing variety of technologies, products and services based upon stem cells, revenues related to stem cell therapies will increase dramatically.


 

Read more or acquire the full report here:

 

Important Note
Information for this "Registered Trial" report was gathered by the third party research firm Kalorama Information, using both primary and secondary research. Primary research methods include telephone interviews and email correspondence with company representatives, researchers and physicians; secondary sources include comprehensive research of company reports and literature, government documents and databases, research journals and reports and general medical and business journals. Forecast dollar figures represent the estimated global market and are expressed in current dollars. Forecasts are provided through 2025. The size of each market segment refers to manufacturers' revenues. 
 
About NeoStem, Inc.
NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of novel cell based personalized medicine therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The combination of a rich therapeutics pipeline and externally recognized in-house manufacturing expertise has created an organization with unique capabilities for cost effective and accelerated product development. www.neostem.com         
 
Note: We have initiated coverage on NeoStem (NASDAQ(NBS), a leading edge cell therapy bio-tech company. We have taken a position in the stock for the SWI services and portfolio. In our opinion the stock is currently dramatically undervalued. Please go to www.stockwatchindex.com/stock-watch-index/neostem for more detail.

Rainer Poertner
StockWatchIndex, LLC
Chief Analyst
About SWI
SWI is a leading edge PR and Information Marketing Service with a highly frequented web site www.stockwatchindex.com and its "Rise Above The Noise" newsletter, which informs you about new and promising discoveries. The weekly "SWI QuickPicks" Ratings Report keeps you informed about newly initiated stocks and potential upgrades and downgrades in the QuickPicks section on our SWI website. SWI QuickPicks represent the consolidated opinions of carefully selected financial analyst blogs and opinions of Wall Street firms that we respect and frequently sample. We  have not been compensated by the companies and do not necessarily hold positions in any of these stocks.  You can conveniently follow the live links for each of these stocks on http://www.stockwatchindex.com/swi-quickpicks for more detail.  SWI's periodical "Portfolio Performance Report" frequently updates on the performance of the stocks that we have purchased and are holding in the SWI portfolio.  Please do not miss the wealth of frequently updated news, research reports and other valuable information elsewhere on SWI, especially for the stocks on our WatchIndex page. Watch a full range of CEO and analyst interviews on our Strategic Partner site www.wideworldofstocks.com.  
Facebook
Twitter
LinkedIn
Google +
StockWatchIndex
 
Good luck and please pass this newsletter on to a friend
to continue building our community.
 

StockWatchIndex (SWI) is not a registered investment adviser and makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in the publications for its Stock Watch List or on its web sites. The provided information is not to be construed as personal financial advice, or a solicitation to buy or sell stock. Some information has been generated by what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrant any results from use of the information. We have contracted with (NBS) and some of the other companies we represent as public relations consultants to keep the market and especially our subscribers informed about the company and are being compensated in cash and/or stock and stock options. We are also frequently acquiring positions in stocks in our WatchList section for our own investment purposes. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein.Be aware that investing into penny stocks represents a high risk investment and you can potentially loose your entire investment. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in its Stock Watch List or on its web sites. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. StockWatchIndex expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. The included information is subject to change without notice..

Copyright © 2015 StockWatchIndex, LLC, All rights reserved.


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp